Lee Sun-Ho, Tatsui Claudio E, Ghia Amol J, Amini Behrang, Li Jing, Zavarella Salvatore M, Tannir Nizar M, Brown Paul D, Rhines Laurence D
Departments of Neurosurgery, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Unit 442, Houston, TX, 77030, USA.
Department of Neurosurgery, Samsung Medical Center, School of Medicine, Sungkyunkwan University, Seoul, South Korea.
J Neurooncol. 2016 Feb;126(3):509-17. doi: 10.1007/s11060-015-1990-z. Epub 2015 Dec 7.
The aim of this study was to determine the predictability of vertebral compression fracture (VCF) development applying the spinal instability neoplastic score (SINS) prior to delivery of stereotactic spinal radiosurgery (SSRS) for spinal metastases. From two prospective cohorts of SSRS for spinal metastases, we selected patients with a low degree of cord compression or cauda equine from C3 to S1 and analyzed 79 patients enrolled according to binary SINS criteria. The primary endpoint was the development of a de novo VCF or progression of an existing fracture after SSRS. We identified 32 fractures (40.5%): 19 de novo and 13 progressive. The mean time to fracture after SSRT was 3.3 months (range, 0.4-34.1 months). In 41 patients with low SINS (0-6), 7 patients (17.1%) developed a fracture after SSRS. In 38 patients with high SINS (7-12), 25 (65.8%) developed a fracture. Among the 32 fractures, 15 were symptomatic. Patients with high SINS were more likely to experience symptomatic fractures (31.6%) than were patients with lower SINS (7.4%). On univariate and multivariate analysis, 24-month fracture-free rates were 78.7 and 33.7% in low and high SINS group, respectively and high SINS was found to be a significant risk factor for VCFs and symptomatic fractures (respectively, HR 5.6, p = 0.04; HR 5.3, p = 0.01). SINS is a useful tool for predicting the development of VCF after SSRS for spinal metastases. Prophylactic cement augmentation should not be considered for patients with lower SINS, since the risk of fracture is low.
本研究的目的是确定在立体定向脊柱放射外科手术(SSRS)治疗脊柱转移瘤之前,应用脊柱不稳定肿瘤评分(SINS)来预测椎体压缩骨折(VCF)发生的可预测性。从两个脊柱转移瘤的SSRS前瞻性队列中,我们选择了脊髓受压程度低或马尾神经受压程度低且椎体节段从C3至S1的患者,并根据二元SINS标准分析了79例入组患者。主要终点是SSRS后新发VCF或现有骨折的进展情况。我们共识别出32例骨折(40.5%):19例新发骨折和13例进展性骨折。SSRT后发生骨折的平均时间为3.3个月(范围为0.4 - 34.1个月)。在41例SINS评分低(0 - 6分)的患者中,7例(17.1%)在SSRS后发生骨折。在38例SINS评分高(7 - 12分)的患者中,25例(65.8%)发生骨折。在这32例骨折中,15例有症状。SINS评分高的患者比SINS评分低的患者更易发生有症状的骨折(分别为31.6%和7.4%)。单因素和多因素分析显示,SINS评分低和高的组中24个月无骨折发生率分别为78.7%和33.7%,并且发现高SINS是VCF和有症状骨折的显著危险因素(分别为HR 5.6,p = 0.04;HR 5.3,p = 0.01)。SINS是预测脊柱转移瘤SSRS后VCF发生的有用工具。对于SINS评分低的患者,不应考虑预防性骨水泥强化,因为骨折风险较低。